Medigene (ETR:MDG1) Shares Up 1.4%

Medigene AG (ETR:MDG1)’s share price shot up 1.4% during mid-day trading on Wednesday . The stock traded as high as €4.07 ($4.79) and last traded at €3.98 ($4.68). 19,769 shares changed hands during mid-day trading, a decline of 94% from the average session volume of 306,207 shares. The stock had previously closed at €3.92 ($4.61).

The company’s fifty day moving average is €3.96. The company has a debt-to-equity ratio of 9.70, a current ratio of 3.23 and a quick ratio of 3.16. The company has a market cap of $97.64 million and a price-to-earnings ratio of -3.38.

About Medigene (ETR:MDG1)

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies.

Recommended Story: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.